Tanaka Yu, Nagano China, Sakakibara Nana, Okada Eri, Aoyama Shuhei, Kimura Yuka, Inoki Yuta, Ichikawa Yuta, Ueda Chika, Kitakado Hideaki, Horinouchi Tomoko, Yamamura Tomohiko, Ishimori Shingo, Iijima Kazumoto, Nozu Kandai, Morisada Naoya
Department of Pediatrics, Kobe University Graduate School of Medicine, 7-5-1, Kusunoki-Cho, Chuo-Ku, Kobe, Hyogo, 650-0017, Japan.
Hyogo Prefectural Kobe Children's Hospital, 1-6-7, Minatojimaminami-Machi, Chuo-Ku, Kobe, Hyogo, 650-0047, Japan.
Clin Exp Nephrol. 2025 Feb 20. doi: 10.1007/s10157-025-02629-4.
Autosomal dominant tubulointerstitial kidney disease (ADTKD) is characterized by tubular atrophy, interstitial fibrosis, and progressive kidney dysfunction. Its causative genes include UMOD, MUC1, REN, HNF1B, and SEC61A1. ADTKD contributes to unexplained chronic kidney disease (CKD), and many cases remain genetically undiagnosed. This study aimed to elucidate the clinical features of patients genetically diagnosed with ADTKD in Japan.
We included individuals with suspected congenital anomalies of the kidney and urinary tract, nephronophthisis, polycystic kidney disease, or ADTKD. Genetic analyses using direct sequencing, short-read next-generation sequencing (SRS), and/or long-read next-generation sequencing (LRS) were performed on 1097 families. Patients with ADTKD-HNF1B were excluded due to prior reporting.
Variants in UMOD, MUC1, REN, and SEC61A1 were identified in 52 patients from 40 families (18, 16, 5, and 1 family, respectively). The median age at diagnosis was 38.5 years, and the urinary protein-to-creatinine ratio was 0.05 g/gCr. End-stage kidney disease was present at diagnosis in 37% of patients. Genetic testing was performed in 58% due to suspected ADTKD based on pathology or clinical course and in 38% due to unexplained CKD. Kidney biopsies were performed in 55%, with ADTKD confirmed pathologically in 41%. SRS and LRS were used in 55% and 30% of all families, respectively; for ADTKD-MUC1, 75% of families were analyzed using LRS.
Clinical and pathological diagnosis of ADTKD remains challenging, emphasizing the importance of comprehensive genetic testing. Enhanced access to advanced genetic testing such as LRS is essential to improve diagnostic precision and management.
常染色体显性遗传性肾小管间质性肾病(ADTKD)的特征为肾小管萎缩、间质纤维化和进行性肾功能不全。其致病基因包括UMOD、MUC1、REN、HNF1B和SEC61A1。ADTKD是不明原因慢性肾脏病(CKD)的病因之一,许多病例在基因层面仍未得到诊断。本研究旨在阐明日本基因诊断为ADTKD患者的临床特征。
我们纳入了疑似患有肾和尿路先天性异常、肾单位肾痨、多囊肾病或ADTKD的个体。对1097个家庭进行了直接测序、短读长下一代测序(SRS)和/或长读长下一代测序(LRS)的基因分析。由于之前已有报道,ADTKD-HNF1B患者被排除在外。
在来自40个家庭的52例患者中鉴定出UMOD、MUC1、REN和SEC61A1基因变异(分别为18、16、5和1个家庭)。诊断时的中位年龄为38.5岁,尿蛋白肌酐比值为0.05 g/gCr。37%的患者在诊断时已处于终末期肾病。58%的患者因基于病理或临床病程怀疑为ADTKD而进行了基因检测,38%的患者因不明原因的CKD进行了基因检测。55%的患者进行了肾活检,其中41%经病理证实为ADTKD。所有家庭中分别有55%和30%使用了SRS和LRS;对于ADTKD-MUC1,75%的家庭使用LRS进行分析。
ADTKD的临床和病理诊断仍然具有挑战性,凸显了全面基因检测的重要性。增加对LRS等先进基因检测的获取途径对于提高诊断准确性和管理水平至关重要。